This video transcript details the pathological approach to diagnosing a highly atypical, pleomorphic spindled cell tumor found in the sun-damaged skin of an older patient, typically presenting as a red, scaly nodule. The primary differential diagnosis (DDx) includes Atypical Fibroxanthoma (AFX), Spindle Cell Squamous Cell Carcinoma (SCC), and Spindled Melanoma.
The key diagnostic challenge lies in distinguishing AFX—which is confined to the dermis and rarely metastasizes—from an Undifferentiated Sarcoma (or Pleomorphic Dermal Sarcoma, PDS). The speaker emphasizes that morphology and initial immunohistochemical (IHC) results are often indistinguishable; therefore, the crucial deciding factor is the depth of invasion. If the tumor is large and invades the subcutaneous fat, it must be diagnosed as a malignant sarcoma. For transected specimens, the pathologist is advised to report the differential and insist on wide excision (Mohs) to fully assess depth and margins.
Summary of the Transcript: Atypical Spindled Cell Tumors of the Skin
0:00 Case Presentation: The discussion centers on a common clinical finding: a red, scaly nodule on the sun-damaged scalp, which clinicians often suspect is Squamous Cell Carcinoma (SCC).
0:16 Histology: The shave biopsy reveals a highly atypical, pleomorphic, spindled cell tumor filling the dermis, characterized by ugly cells and numerous tripolar or stick-figure mitoses.
0:34 Core Differential Diagnosis (DDx): The four main considerations for this presentation are Atypical Fibroxanthoma (AFX), Spindle Cell Squamous Cell Carcinoma, Spindled Melanoma, and occasionally Angiosarcoma.
0:59 Recommended IHC Markers: The speaker advises a standard set of stains to rule out the specific differentials: S100/Sox10 (Melanoma), P63/Keratins (SCC), ERG/CD31 (Vascular), and Desmin (Rhabdomyosarcoma).
1:13 Marker Preference Note: The speaker expresses preference for ERG/CD31 over CD34 for vascular tumors, noting CD34 is dirty, non-specific, and negative in some Angiosarcomas.
1:46 Disdain for Vimentin: The speaker strongly discourages the use of Vimentin, arguing it is entirely non-specific and has never changed a diagnosis in their experience.
2:23 AFX vs. Undifferentiated Sarcoma: A key diagnostic challenge is differentiating AFX from an Undifferentiated Sarcoma (formerly known as MFH, or Pleomorphic Dermal Sarcoma, PDS). Morphologically and by stain (both are negative for specific markers), they are identical.
2:43 Key Takeaway: Depth is Destiny: The crucial difference between AFX and Undifferentiated Sarcoma is size and depth. If the lesion is large and invades the subcutaneous fat, it is considered a fully malignant Sarcoma. If it is confined entirely to the dermis, it is classified as AFX, which has a very low risk of aggressive behavior.
3:16 Aggressive Behavior: Lesions on the head and neck, even those suspected to be AFX, are statistically more aggressive (about 30% risk of metastasis) compared to other sites.
3:50 Pathologist’s Role and Management: For transected biopsy specimens where depth cannot be confirmed, the pathologist must clearly state the differential (AFX vs. Sarcoma/PDS) and recommend a subsequent wide excision (Mohs) to determine depth and ensure negative margins.